Long COVID blood filter study pulled before it began
NCT ID NCT06637800
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study planned to test a blood filter device called Seraph 100 in 100 people with long COVID. The device was meant to remove harmful substances from the blood during two sessions on consecutive days. However, the study was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Seraph 100 blood filter device
- What this could lead to
- If it had worked, this could have pointed toward a new way to treat long COVID by filtering the blood.
- What could go wrong
- The study was withdrawn before any patients were enrolled, so we have no data on safety or effectiveness. The approach is experimental and unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Angeles Tijuana
Tijuana, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Could exercise retrain the heart in long COVID?
- Can brain games and gentle currents lift long COVID brain fog?
- Can brain training zap long COVID brain fog?
- Ear device zaps vagus nerve in bid to quiet long COVID fatigue and brain fog
- Smartphone therapy could ease long COVID's mental toll